An Evidence-Based Rationale for Dose De-escalation of Subcutaneous Atezolizumab.

ABSTRACT:

Background

Atezolizumab is a programmed death-ligand 1 (PD-L1) checkpoint inhibitor for the treatment of different forms of cancer. The subcutaneous formulation of atezolizumab has recently received approval. However, treatment with atezolizumab continues to be expensive, and the number of patients needing treatment with this drug continues to increase.

Objective

We propose two alternative dosing regimens for subcutaneous atezolizumab to reduce drug expenses while ensuring effective exposure; one may be directly implemented in the clinic.

Patients and methods

We developed two alternative dose interval prolongation strategies based on pharmacokinetic modeling and simulation. The first dosing regimen was based on patients' weight while maintaining equivalent systemic dr

SUBMITTER: Kicken MP 

PROVIDER: S-EPMC11393195 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature